Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $42.00

Cullinan Therapeutics (NASDAQ:CGEM) had its target price increased by stock analysts at Wedbush from $39.00 to $42.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price target would indicate a potential upside of 114.29% from the stock’s previous close.

A number of other research firms have also issued reports on CGEM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. BTIG Research boosted their price objective on Cullinan Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Cullinan Therapeutics in a report on Monday, June 8th. Finally, Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.86.

Cullinan Therapeutics Price Performance

Shares of NASDAQ:CGEM opened at $19.60 on Thursday. The firm has a market capitalization of $1.26 billion, a PE ratio of -6.32 and a beta of 0.01. Cullinan Therapeutics has a 1 year low of $5.68 and a 1 year high of $19.94. The firm’s 50-day moving average is $16.81 and its two-hundred day moving average is $14.99.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01). Analysts expect that Cullinan Therapeutics will post -3.03 EPS for the current fiscal year.

Insider Activity at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $17.82, for a total value of $142,560.00. Following the transaction, the insider owned 162,844 shares in the company, valued at approximately $2,901,880.08. This represents a 4.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Several hedge funds have recently added to or reduced their stakes in CGEM. Caitong International Asset Management Co. Ltd raised its holdings in Cullinan Therapeutics by 62.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,696 shares of the company’s stock worth $28,000 after purchasing an additional 1,036 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Cullinan Therapeutics in the 4th quarter valued at $31,000. CWM LLC grew its position in shares of Cullinan Therapeutics by 51.5% in the 4th quarter. CWM LLC now owns 3,876 shares of the company’s stock valued at $40,000 after buying an additional 1,318 shares during the last quarter. Allworth Financial LP acquired a new stake in Cullinan Therapeutics during the 2nd quarter worth $53,000. Finally, Quantbot Technologies LP acquired a new stake in Cullinan Therapeutics during the 2nd quarter worth $53,000. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Analysts currently assign Cullinan Therapeutics an average rating of “Moderate Buy”, indicating generally favorable sentiment toward the biotechnology company’s pipeline and longer-term prospects. Cullinan Therapeutics Receives Average Rating of Moderate Buy from Analysts
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $30 price target for CGEM, implying substantial upside from the stock’s recent level around $19.60. The firm’s published estimates show expected losses narrowing modestly during 2027, although the company is still projected to remain unprofitable. HC Wainwright analyst estimates for Cullinan Therapeutics
• Neutral Sentiment: Reported short interest was listed at zero shares with a zero-day days-to-cover ratio. Because the data showed no measurable short position and an unusable percentage change, it provides little meaningful indication of investor positioning or likely trading pressure.
• Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of $3.53 per share from a $3.42 loss, and reduced its Q3 2026 forecast to a $0.90 loss from $0.87. The firm also cut its Q4 2026 estimate to a $0.93 loss from $0.90, signaling somewhat higher expected near-term expenses.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.